コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 (Long-Term Intervention With Pravastatin in Ischemic Disease).
2 ttempts to develop alternative therapies for ischemic disease.
3 otential therapeutic target for treatment of ischemic disease.
4 V) outcomes in heart failure (HF) and stable ischemic disease.
5 tion construct for the clinical treatment of ischemic disease.
6 rcome to advance regenerative approaches for ischemic disease.
7 r treating hyperpermeability associated with ischemic disease.
8 en implicated in the pathogenesis of retinal ischemic disease.
9 Diabetes is a major risk factor for ischemic disease.
10 ndings into new treatments for patients with ischemic disease.
11 of hypoxia tolerance with relevance to human ischemic disease.
12 vascularizing tissue constructs and treating ischemic disease.
13 ansplantation, an association independent of ischemic disease.
14 ikely owing to the inexorable progression of ischemic disease.
15 s HIF as a potential target for treatment of ischemic disease.
16 el-1 may be a useful tool for the therapy of ischemic disease.
17 glucose (simulated ischemia) as a model for ischemic disease.
18 nslational modification related to aging and ischemic disease.
19 and clinical evaluation for the treatment of ischemic diseases.
20 logical cues, holds great potential to treat ischemic diseases.
21 strategies based on EPC in the treatment of ischemic diseases.
22 ity and inflammatory, neurodegenerative, and ischemic diseases.
23 strategy in diabetic patients with critical ischemic diseases.
24 esis is a promising therapeutic approach for ischemic diseases.
25 ) are known to promote neovascularization in ischemic diseases.
26 nipulation of the HIF prolyl hydroxylase for ischemic diseases.
27 ncluding cancer, inflammatory disorders, and ischemic diseases.
28 inhibitors in retinal vascular occlusive and ischemic diseases.
29 od vessel tone that may affect the course of ischemic diseases.
30 involvement of RTP801 in the pathogenesis of ischemic diseases.
31 genesis represents a promising treatment for ischemic diseases.
32 y be useful in the treatment of inflammatory/ischemic diseases.
33 rugs, inhibit these deleterious processes in ischemic diseases affecting skeletal muscle, and therefo
34 noncardiac surgery may be a useful marker of ischemic disease and a predictor of 6-month prognosis.
37 VEGF induces vascular permeability (VP) in ischemic diseases and cancer, leading to many pathophysi
38 dominant cap-binding protein (1% hypoxia or ischemic diseases and cancerous tumors), and where both
41 exciting possibilities for the treatment of ischemic disease, and furthermore allows the selective t
42 rhythm, and insignificant valvular or active ischemic disease, and groups were matched for age, gende
44 approximately 280 lower-limb amputations for ischemic disease are performed per million people each y
45 uring exercise has been used as a marker for ischemic disease, arrhythmogenic substrate and the long
46 are promising candidates for cell therapy of ischemic diseases, as less than 10% of patients with an
47 teries is essential for revascularization in ischemic diseases, but this is impaired in diabetes.
49 etic resistance (age 74.5 +/- 8.2 years; 75% ischemic disease; ejection fraction 31 +/- 15%) and cont
50 anies many forms of heart disease, including ischemic disease, hypertension, heart failure, and valvu
52 r cells (EPCs) are used for the treatment of ischemic diseases in clinical trials, and circulating EP
53 ts used in the treatment of vasoconstrictive/ischemic diseases including pulmonary artery hypertensio
54 een implicated in the development of various ischemic diseases, including ischemic retinopathies.
55 [Long-term Intervention with Pravastatin in Ischemic Disease]) individually demonstrated reductions
56 d Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) studies collectively accumulate
59 he biology of Mesp1-CPCs in cell culture and ischemic disease models is an important initial step tow
60 s a potential target for treating anemia and ischemic diseases, motivating the development of inhibit
62 evelopment of therapeutic strategies against ischemic diseases, particularly of the cerebro-cardiovas
64 ve stress that accompanies acute and chronic ischemic disease perturbs connexon forward trafficking.
65 Acute myocardial infarction (MI) is a severe ischemic disease responsible for heart failure and sudde
66 of proangiogenic cells for the treatment of ischemic diseases.Soluble vascular endothelial growth fa
67 ial for hemostasis, but may also cause acute ischemic disease states such as myocardial infarction or
68 rtance, not only in patients with hypoxic or ischemic disease states, but also in patients with other
70 d Long-term Intervention with Pravastatin in Ischemic Disease study, have indicated that cardiovascul
73 genesis and can potentially be used to treat ischemic diseases, yet in clinical trials VEGF has not f
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。